Second-line anti-tuberculosis drug exposure thresholds predictive of adverse events in multidrug-resistant tuberculosis treatment

Multidrug-resistant tuberculosis (MDR-TB) remains a major public health problem [1]. The introduction of new (bedaquiline) and repurposed drugs (linezolid and clofazimine) is expected to improve treatment outcomes [2], but adverse events (AEs) related to these drugs have been frequently reported during the long-term MDR-TB treatment [3]. As many as 8.4% of patients with MDR-TB experienced serious AEs, including corrected QT interval by Fridericia's formula (QTcF) above 500ms, bone marrow suppression, peripheral neuropathy, and kidney/liver failure, resulting in treatment failure, as well as major morbidity and even death [2, 3].

Source: International Journal of Infectious Diseases - January 2, 2024 Category: Infectious Diseases Authors: Sainan Wang, Lina Davies Forsman, Chunhua Xu, Haoyue Zhang, Yue Zhu, Ge Shao, Shanshan Wang, Jiayi Cao, Haiyan Xiong, Katarina Niward, Thomas Sch ön, Judith Bruchfeld, Limei Zhu, Jan-Willem Alffenaar, Yi Hu Source Type: research